ES2913977T3 - Compuestos para uso en el tratamiento o profilaxis del dolor, la inflamación y/o la autoinmunidad - Google Patents

Compuestos para uso en el tratamiento o profilaxis del dolor, la inflamación y/o la autoinmunidad Download PDF

Info

Publication number
ES2913977T3
ES2913977T3 ES20703152T ES20703152T ES2913977T3 ES 2913977 T3 ES2913977 T3 ES 2913977T3 ES 20703152 T ES20703152 T ES 20703152T ES 20703152 T ES20703152 T ES 20703152T ES 2913977 T3 ES2913977 T3 ES 2913977T3
Authority
ES
Spain
Prior art keywords
polymorph
pain
polymorphic form
treatment
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20703152T
Other languages
English (en)
Spanish (es)
Inventor
Eli Kaplan
Robert Hett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaremed Ltd
Original Assignee
Novaremed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaremed Ltd filed Critical Novaremed Ltd
Application granted granted Critical
Publication of ES2913977T3 publication Critical patent/ES2913977T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES20703152T 2019-01-23 2020-01-22 Compuestos para uso en el tratamiento o profilaxis del dolor, la inflamación y/o la autoinmunidad Active ES2913977T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19153315 2019-01-23
PCT/EP2020/051528 WO2020152226A1 (en) 2019-01-23 2020-01-22 Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity

Publications (1)

Publication Number Publication Date
ES2913977T3 true ES2913977T3 (es) 2022-06-07

Family

ID=65228356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20703152T Active ES2913977T3 (es) 2019-01-23 2020-01-22 Compuestos para uso en el tratamiento o profilaxis del dolor, la inflamación y/o la autoinmunidad

Country Status (17)

Country Link
US (1) US11891350B2 (enExample)
EP (1) EP3860582B1 (enExample)
JP (2) JP7611148B2 (enExample)
KR (1) KR20210119403A (enExample)
CN (1) CN113329746B (enExample)
AU (1) AU2020210831B2 (enExample)
BR (1) BR112021019476A2 (enExample)
CA (1) CA3118996A1 (enExample)
DK (1) DK3860582T3 (enExample)
ES (1) ES2913977T3 (enExample)
IL (1) IL282718B2 (enExample)
PL (1) PL3860582T3 (enExample)
PT (1) PT3860582T (enExample)
RS (1) RS63270B1 (enExample)
SG (1) SG11202111773QA (enExample)
WO (1) WO2020152226A1 (enExample)
ZA (1) ZA202107346B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939578A1 (en) * 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
WO2026037478A1 (en) 2023-08-11 2026-02-19 Novaremed AG (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642290B2 (en) 2002-10-03 2010-01-05 Novaremed Limited Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
US7674829B2 (en) 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
WO2011030205A1 (en) 2009-09-09 2011-03-17 Novaremed Ltd. N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation
US8802734B2 (en) 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
GB0916073D0 (en) 2009-09-14 2009-10-28 Cintec Int Ltd Improvements in and relating to building anchor systems
CN103998420B (zh) * 2011-12-08 2018-04-17 诺瓦麦有限公司 (s)2‑n(3‑o‑(丙‑2‑醇)‑1‑丙基‑4‑羟基苯)‑3‑苯基丙酰胺的分离的立体异构形式

Also Published As

Publication number Publication date
PT3860582T (pt) 2022-07-08
KR20210119403A (ko) 2021-10-05
SG11202111773QA (en) 2021-11-29
US20220002228A1 (en) 2022-01-06
CA3118996A1 (en) 2020-07-30
US11891350B2 (en) 2024-02-06
JP7611148B2 (ja) 2025-01-09
JP2025036479A (ja) 2025-03-14
RS63270B1 (sr) 2022-06-30
EP3860582A1 (en) 2021-08-11
IL282718A (en) 2021-06-30
PL3860582T3 (pl) 2022-08-01
JP2022518288A (ja) 2022-03-14
ZA202107346B (en) 2023-10-25
AU2020210831B2 (en) 2025-02-13
BR112021019476A2 (pt) 2021-11-30
EP3860582B1 (en) 2022-05-04
CN113329746A (zh) 2021-08-31
IL282718B1 (en) 2024-04-01
WO2020152226A1 (en) 2020-07-30
IL282718B2 (en) 2024-08-01
CN113329746B (zh) 2025-05-02
AU2020210831A1 (en) 2021-05-20
DK3860582T3 (da) 2022-05-23

Similar Documents

Publication Publication Date Title
ES2591110T3 (es) Usos terapéuticos de compuestos que tienen actividad SERT, 5-HT3 y 5-HT1A combinada
JP5371790B2 (ja) 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、5−ht3および5−ht1a活性を有する化合物としての1−[2−(2,4−ジメチルフェニルスルファニル)フェニル]ピペラジン
ES2528215T3 (es) Tapentadol para tratamiento del dolor debido a la artrosis
DK2488170T3 (en) FORMATIONS comprising tramadol and celecoxib, FOR THE TREATMENT OF PAIN
JP2025036479A (ja) 疼痛、炎症および/または自己免疫の処置または予防における使用のための化合物
JP2013531008A (ja) 下肢静止不能症候群を治療する方法
ES2505325T3 (es) Bencenopropanamida N-sustituida o derivados de bencenopropenamida para su uso en el tratamiento del dolor
ES2632919T3 (es) Forma cristalina de sal de (R, R)-Tramadol-(S)-naproxeno para el tratamiento del dolor
JP6016179B2 (ja) 疼痛の治療又は予防用医薬組成物
US20230373940A1 (en) Carboxylic diarylthiazepineamines and uses thereof
US8802734B2 (en) Method of treating or preventing pain
ES2650441T3 (es) Composición farmacéutica que comprende (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano-[3,4,b]indol]-4-amina y paracetamol o propacetamol
RU2733719C1 (ru) Комбинация для лечения функциональных заболеваний органов желудочно-кишечного тракта
HK40061961B (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
HK40061961A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
CN111050800B (zh) 血清素3受体激动剂对疼痛的治疗
ES2366850A1 (es) Composiciones que comprenden tramadol y el co-cristal de celecoxib y l-prolina en el tratamiento del dolor.
WO2014164784A1 (en) Hdac inhibitor polymorphic forms and methods of use